The Rebif® new formulation story: It's not trials and error

Drugs in R and D

Volumn 8, Issue 6, 2007, Pages 335-348

  Jaber, Amer ^a,b   Driebergen, Reinoud ^a,b   Giovannoni, Gavin ^c,d   Schellekens, Huub ^e   Simsarian, James ^f   Antonelli, Michele ^a,b  

^a Serono International SA   (Switzerland)

^b MERCK KGAA   (Germany)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d BARTS HEALTH NHS TRUST   (United Kingdom)

^e UTRECHT UNIVERSITY   (Netherlands)

^f Neurology Center of Fairfax   (United States)

Author keywords

Interferon beta 1a, therapeutic use; Interferon beta, therapeutic use; Multiple sclerosis

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; BOVINE SERUM ALBUMIN; CAPOXONE; DRUG VEHICLE; GLATIRAMER; HUMAN INSULIN; HUMAN SERUM ALBUMIN; INTERFERON BETA SERINE; NATALIZUMAB; NEUTRALIZING ANTIBODY; PLACEBO; REBIF NEW FORMULATION 1; REBIF NEW FORMULATION 2; RECOMBINANT BETA INTERFERON; RECOMBINANT INTERFERON; UNCLASSIFIED DRUG;

CELL ASSAY; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG FORMULATION; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; INJECTION SITE; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; LYMPHOCYTE PROLIFERATION; MULTIPLE SCLEROSIS; NAUSEA AND VOMITING; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; RIGOR; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; CHEMISTRY; DRUG SCREENING; INTRAVENOUS DRUG ADMINISTRATION; VEHICLES;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG EVALUATION, PRECLINICAL; HUMANS; INJECTIONS, INTRAVENOUS; INTERFERON-BETA; MULTIPLE SCLEROSIS; VEHICLES;

EID: 35548956505     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200708060-00002     Document Type: Review

References (73)

1. Walsh G. Biopharmaceutical benchmarks: 2003. Nature Biotechnology 2003 Aug; 21 (8): 865-70
2. Walsh JC. Current status of biopharmaceuticals: approved products and trends in approvals. In: Knablein J, editor. Modern biopharmaceuticals: design, development and optimization. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA, 2005: 1-34
3. Hermeling S, Crommelin DJ, Schellekens H, et al. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 2004 Jun; 21 (6): 897-903
4. Schellekens H, Bausch J. Biopharmaceutical molecules are not created equally. Pharm J 2002 268: 300-1
5. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000 Jun; 47 (6): 707-17
6. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996 Apr; 46 (4): 907-11
7. Chofflon M. Mechanisms of action for treatments in multiple sclerosis: does a heterogeneous disease demand a multi-targeted therapeutic approach? BioDrugs 2005; 19 (5): 299-308
8. Giovannoni G, Ebers G. Multiple sclerosis: the environment and causation. Curr Opin Neurol 2007 Jun; 20 (3): 261-8
9. Lu Y, Yang J, Sega E. Issues related to targeted delivery of proteins and peptides. AAPS J 2006; 8 (3): E466-78
10. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 2002 Nov; 24 (11): 1720-40; discussion 1719
11. Vartanian TK, Zamvil SS, Fox E, et al. Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis. Neurology 2004 Dec 14; 63 (11 Suppl. 5): S42-9
12. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354 (9): 899-910
13. Summary of product characteristics (Tysabri 300 mg concentrate for solution for infusion) [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/tysabri/H-603-PI-en.pdf [Accessed 2007 Jul 4]
14. Freedman MS, Patry DG, Grand'Maison F, et al. Treatment optimization in multiple sclerosis. Can J Neurol Sci 2004 May; 31 (2): 157-68
15. Salama HH, Hong J, Zang YC, et al. Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis. Brain 2003 Dec; 126 (Pt 12): 2638-47
16. Teitelbaum D, Brenner T, Abramsky O, et al. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult Scler 2003 Dec; 9 (6): 592-9
17. Kobata A. Structures and functions of the sugar chains of glycoproteins. Eur J Biochem 1992 Oct 15; 209 (2): 483-501
18. Betaseron prescribing information [online]. Available from URL: http://berlex.bayerhealthcare.com/html/products/pi/Betaseron_PI.pdf [Accessed 2007 Jul 18]
19. Schellekens H. The immunogenicity of biopharmaceuticals. Neurology 2003; 61 (5): S11-2
20. European Agency for the Evaluation of Medicinal Products. Rebif European public assessment report [online]. Available from URL: http://www.emea.eu.int/ humandocs/Humans/EPAR/rebif/rebif.htm [Accessed 2007 Jul 19]
21. European Agency for the Evaluation of Medicinal Products. Initial scientific discussion for approval of Avonex [online]. Available from URL: http://www.emea.eu.int/humandocs/PDFs/EPAR/avonex/106396en6.pdf [Accessed 2007 Jul 19]
22. European Agency for the Evaluation of Medicinal Products. Avonex European public assessment report [online]. Available from URL: http://www.emea.eu.int/ humandocs/Humans/EPAR/avonex/avonex.htm [Accessed 2007 Jul 19]
23. Ross C, Clemmesen KM, Svenson M, et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000 Nov; 48 (5): 706-12
24. Cook SD, Quinless JR, Jotkowitz A, et al. Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients. Neurology 2001 Sep 25; 57 (6): 1080-4
25. Scagnolari C, Bellomi F, Turriziani O, et al. Neutralizing and binding antibodies to IFN-beta: relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-beta preparations. J Interferon Cytokine Res 2002 Feb; 22 (2): 207-13
26. Bertolotto A, Malucchi S, Sala A, et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 2002 Aug; 73 (2): 148-53
27. Gribben JG, Devereux S, Thomas NS, et al. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 1990 Feb 24; 335 (8687): 434-7
28. Karpusas M, Whitty A, Runkel L, et al. The structure of human interferon-beta: implications for activity. Cell Molec Life Sci 1998 Nov; 54 (11): 1203-16
29. Runkel L, Meier W, Pepinsky RB, et al. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm Res 1998 Apr; 15 (4): 641-9
30. European Agency for the Evaluation of Medicinal Products. Chapter 15. Medicinal products GMP inspection and batch certification: scope and coverage, 1999 [online]. Available from URL: http://www.emea.europa.eu/Inspections/docs/ ch/mraswiss.pdf [Accessed 2007 Jul 19]
31. Velagaleti R, Burns P, Gill M. Analytical support for drug manufacturing in the United States: from active pharmaceutical ingredient synthesis to drug product shelf-life. Drug Inf J 2003; 37: 407-38
32. Li D, Paty D, UBC MS/MRI Analysis Research Group, et al. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999; 46: 197-206
33. Li DK, Zhao GJ, Paty DW. University of British Columbia MS/MRI Analysis Research Group. The SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 2001 Jun 12; 56 (11): 1505-13
34. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis [published erratum appears in Lancet 1999 Feb 20; 353 (9153): 678]. Lancet 1998 Nov 7; 352 (9139): 1498-504
35. PRISMS Study Group, Group: UoBCMMA. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56 (12): 1628-36
36. Gottberg K, Gardulf A, Fredrikson S. Interferon-beta treatment for patients with multiple sclerosis: the patients' perceptions of the side-effects. Mult Scler 2000 Oct; 6 (5): 349-54
37. Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 1999 Nov 10; 53 (8): 1622-7
38. Mikol D, Lopez-Bresnahan M, Taraskiewicz S, et al. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Mult Scler 2005 Oct; 11 (5): 585-91
39. Gold R, Rieckmann P, Chang P, et al. The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study. Eur J Neurol 2005 Aug; 12 (8): 649-56
40. Sandberg-Wollheim M, Bever C, Carter J, et al. Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis: the EVIDENCE study. J Neurol 2005; 252 (1): 8-13
41. Francis GS, Rice GP, Alsop JC. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005 Jul 12; 65 (1): 48-55
42. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996 Oct; 47 (4): 889-94
43. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998 May; 50 (5): 1266-72
44. Polman C, Kappos L, White R, et al. Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 2003 Jan 14; 60 (1): 37-43
45. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003 Oct 11; 362 (9391): 1184-91
46. Petkau AJ, White RA, Ebers GC, et al. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 2004 Apr; 10 (2): 126-38
47. Perini P, Calabrese M, Biasi G, et al. The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol 2004 Mar; 251 (3): 305-9
48. Kappos L, Clanet M, Sandberg-Wollheim M, et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005 Jul 12; 65 (1): 40-7
49. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002 Apr 27; 359 (9316): 1453-60
50. Panitch H. Differences between IFN beta-1a 44 mcg tiw and 30 mcg qw sustained to 16 months: final EVIDENCE results [abstract]. Int J MS Care 2003 5: 80
51. Clanet M, Radue EW, Kappos L, et al. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002 Nov 26; 59 (10): 1507-17
52. Panitch H, Goodin D, Francis G, et al. for the EVIDENCE Study Group and the University of British Columbia MS/MRI Research Group. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci 2005; 239: 67-74
53. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000 Sep 28; 343 (13): 898-904
54. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56: 1496-504
55. Deisenhammer F, Schellekens H, Bertolotto A. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis. J Neurol 2004 Jun; 251 Suppl. 2: II31-9
56. Merten OW. Development of serum-free media for cell growth and production of viruses/viral vaccines: safety issues of animal products used in serum-free media. Dev Biol 2002; 111: 233-57
57. Committee for Proprietary Medicinal Products (CPMP). European Agency for the Evaluation of Medicinal Products. Evaluation of medicines for human use. Development pharmaceutics for biotechnological and biological products. Annex to note for guidance on development therapeutics, 1999 [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/bwp/032899en.pdf [Accessed 2007 Jul 4]
58. Bosse D, Praus M, Kiessling P, et al. Phase I comparability of recombinant human albumin and human serum albumin. J Clin Pharmacol 2005 Jan; 45 (1): 57-67
59. Jaber A, Baker M. Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays. J Pharm Biomed Anal 2007 Mar 12; 43 (4): 1256-61
60. Bellomi F, Muto A, Palmieri G, et al. Immunogenicity comparison of interferon-beta-1a preparations using the BALB/c mouse model: assessment of a new formulation for use in multiple sclerosis. New Microbiol 2007; 30: 241-6
61. Brearley C, Jaber A, Bertolino M, et al. Assessment of the safety, tolerability, and PK/PD properties of two new formulations of subcutaneously administered IFN-b1a: a double-blind, placebo-controlled comparison with the currently available formulation. Int J Clin Pharmacol Ther 2007; 45 (6): 307-18
62. Giovannoni G, Barbarash O, Casset-Semanaz F, et al. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. Clin Ther 2007; 29 (6): 1128-45
63. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002 Nov 26; 59 (10): 1496-506
64. Phillips JT, Rice G, Frohman E, et al. A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis. Clin Ther 2004 Apr; 26 (4): 511-21
65. Herndon RM, Rudick RA, Munschauer 3rd FE, et al. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis. Mult Scler 2005 Aug; 11 (4): 409-19
66. Bellomi F, Scagnolari C, Tomassini V, et al. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci 2003 Nov 15; 215 (1-2): 3-8
67. Gneiss C, Reindl M, Lutterotti A, et al. Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity. Mult Scler 2004 Oct; 10 (5): 507-10
68. Hochuli E. Interferon immunogenicity: technical evaluation of interferon-alpha 2a. J Interferon Cytokine Res 1997 Jul; 17 Suppl. 1: S15-21
69. Ruiz L, Reyes N, Duany L, et al. Long-term stabilization of recombinant human interferon alpha 2b in aqueous solution without serum albumin. Int J Pharm 2003 Oct 2; 264 (1-2): 57-72
70. Braun A, Kwee L, Labow MA, et al. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res 1997 Oct; 14 (10): 1472-8
71. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002 Jun; 1 (6): 457-62
72. Cramer JA, Cuffel BJ, Divan V, et al. Patient satisfaction with an injection device for multiple sclerosis treatment. Acta Neurol Scand 2006 Mar; 113 (3): 156-62
73. McKeage K, Wagstaff AJ. Subcutaneous interferon-β-1a: new formulation. CNS Drugs 2007; 21 (10): 871-6